Clinical Cancer Research Holland2
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Von Hoff, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Von Hoff, D. D.

Clinical Cancer Research, Vol 4, Issue 5 1079-1086, Copyright © 1998 by American Association for Cancer Research

ARTICLES

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

DD Von Hoff
Cancer Therapy and Research Center, and Department of Medicine, University of Texas Health Science Center at San Antonio, 78245, USA. dvonhoff@saci.org

Unfortunately, the vast majority (90%) of new anticancer agents designed in the laboratory never make it into routine clinical use. The hypothesis of this lecture is that many new agents fail in the clinic because the appropriate clinical trial(s) that could exploit the attributes of the new agent are not performed. An appreciation that both bench and clinical investigations are difficult endeavors should aid in improving clinical trial designs and give the best chance for new agents to be added to our therapeutic armamentarium.


This article has been cited by other articles:


Home page
 JCOHome page
S. Kopetz, M. Overman, D. Z. Chang, K. Y. Glover, I. Shureiqi, R. A. Wolff, J. L. Abbruzzese, and C. Eng
Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway
J. Clin. Oncol., April 20, 2008; 26(12): 2000 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Joffe and F. G. Miller
Rethinking Risk-Benefit Assessment for Phase I Cancer Trials
J. Clin. Oncol., July 1, 2006; 24(19): 2987 - 2990.
[Full Text] [PDF]

Home page
 JCOHome page
C. P. Lee, P. M. Patel, P. J. Selby, B. W. Hancock, I. Mak, L. Pyle, M. G. James, D. A. Beirne, S. Steeds, R. A'Hern, et al.
Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., February 20, 2006; 24(6): 898 - 903.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Goffin, S. Baral, D. Tu, D. Nomikos, and L. Seymour
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
Clin. Cancer Res., August 15, 2005; 11(16): 5928 - 5934.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Lee and L. Feng
Randomized Phase II Designs in Cancer Clinical Trials: Current Status and Future Directions
J. Clin. Oncol., July 1, 2005; 23(19): 4450 - 4457.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
W. Slichenmyer
Clinical Trial Strategies to Facilitate the Transition to Registration-Directed Trials
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 297 - 302.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Schiller
Clinical Trial Design Issues in the Era of Targeted Therapies
Clin. Cancer Res., June 15, 2004; 10(12): 4281S - 4282S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Yovine, M. Riofrio, J.Y. Blay, E. Brain, J. Alexandre, C. Kahatt, A. Taamma, J. Jimeno, C. Martin, Y. Salhi, et al.
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
J. Clin. Oncol., March 1, 2004; 22(5): 890 - 899.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. K. Rowinsky
Signal Events: Cell Signal Transduction and Its Inhibition in Cancer
Oncologist, December 1, 2003; 8(90003): 5 - 17.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. G. Roberts Jr, T. J. Lynch Jr, and B. A. Chabner
The Phase III Trial in the Era of Targeted Therapy: Unraveling the "Go or No Go" Decision
J. Clin. Oncol., October 1, 2003; 21(19): 3683 - 3695.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. K. Rowinsky
Challenges of Developing Therapeutics That Target Signal Transduction in Patients With Gynecologic and Other Malignancies
J. Clin. Oncol., May 15, 2003; 21(90100): 175s - 186.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Nakamura, T. Taniguchi, Y. Funahashi, and K. Yoshimatsu
Effects of ER-37328 on Primary Tumor, Liver Metastasis, and Life Span in a Murine Colon 38 Orthotopic Transplantation Model
Mol. Cancer Ther., January 1, 2003; 2(1): 59 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
J. S de Bono and E. K Rowinsky
Therapeutics targeting signal transduction for patients with colorectal carcinoma
Br. Med. Bull., December 1, 2002; 64(1): 227 - 254.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. L. Rosner, W. Stadler, and M. J. Ratain
Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents
J. Clin. Oncol., November 15, 2002; 20(22): 4478 - 4484.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Niyikiza, S. D. Baker, D. E. Seitz, J. M. Walling, K. Nelson, J. J. Rusthoven, S. P. Stabler, P. Paoletti, A. H. Calvert, and R. H. Allen
Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy
Mol. Cancer Ther., May 1, 2002; 1(7): 545 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Schilsky
End Points in Cancer Clinical Trials and the Drug Approval Process
Clin. Cancer Res., April 1, 2002; 8(4): 935 - 938.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. M. Marx, C. B. Steer, P. Harper, N. Pavlakis, O. Rixe, and D. Khayat
Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock!
J. Clin. Oncol., March 15, 2002; 20(6): 1446 - 1448.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Hidalgo and S. G. Eckhardt
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
J Natl Cancer Inst, February 7, 2001; 93(3): 178 - 193.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. L. Korn, S. G. Arbuck, J. M. Pluda, R. Simon, R. S. Kaplan, and M. C. Christian
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
J. Clin. Oncol., January 1, 2001; 19(1): 265 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Sebastian de Bono, A. G. Dalgleish, J. Carmichael, J. Diffley, F. J. Lofts, D. Fyffe, S. Ellard, R. J. Gordon, C. J. Brindley, and T. R. J. Evans
Phase I Study of ONO-4007, a Synthetic Analogue of the Lipid A Moiety of Bacterial Lipopolysaccharide
Clin. Cancer Res., February 1, 2000; 6(2): 397 - 405.
[Abstract] [Full Text]

Home page
 JCOHome page
E. K. Rowinsky, J. J. Windle, and D. D. Von Hoff
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
J. Clin. Oncol., November 1, 1999; 17(11): 3631 - 3652.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. J. Esteva and G. N. Hortobagyi
Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer
Oncologist, October 1, 1998; 3(5): 300 - 313.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.